Mitochondrial Disorders 1
The Mitochondrial Disorders 1 session will be discussing Molecular and enzymatic diagnosis; biomarkers; therapies in mitochondrial disorders.
This educational activity is supported by an educational grant from Ultragenyx.
Marni Falk, MD
Executive Director, Mitochondrial Medicine Frontier Program
Distinguished Chair in the Department of Pediatrics
Professor, Division of Human Genetics, Department of Pediatrics, University of Pennsylvania Perelman School of Medicine
Children's Hospital of Philadelphia
Marni Falk, MD, speaker for this session, is a consultant for Abliva, AutobahnRX, Casma Therapeutics, Epirium Bio, Inc., Foresite Labs, LLC, HealthCap, IMEL Biotherapeutics, Inc., Minovia Therapeutics, Ltd., Mission Therapeutics, Stealth Biotherapeutics andTaysha Gene Therapies, Inc., is a lecturer for Agios Pharmaceuticals, Inc., and on the advisory board for Khondrion, Larimer Therapeutics, Inc. and RiboNova, Inc., and owns stock in RiboNova, Inc.
Planners, faculty, and others in control of content (either individually or as a group) have no relevant financial relationships with ineligible companies.
All of the relevant financial relationships listed have been mitigated.
Children’s Hospital Colorado is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Children’s Hospital Colorado designates this Other (Internet Live) activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
A general certificate of attendance will be available after the completion of the online evaluation. Claim only credit commensurate of your conference attendance.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance